UNASSIGNED: @entity101 is a serious public health concern with inadequate control of blood pressure (BP) worldwide. Contributing factors include low efficacy of drugs, underuse of combination therapies, irrational combinations, physicians' therapeutic inertia and poor adherence to treatment. Current guidelines recommend the use of initial (dual) combination therapy in high-risk @entity1 for immediate BP response, better short- and long-term BP control, and continued/improved @entity1 adherence. This article aims to review the existing evidence of triple-combination therapies with respect to efficacy, safety and adherence to treatment. It is estimated that three drugs are required to achieve BP control in approximately one-fourth to one-third of @entity1 . Randomised controlled trials (RCTs) have shown that triple combinations of @entity3591 / @entity917 / @entity918 , @entity3591 / @entity9885 / @entity918 and @entity3591 / @entity9887 / @entity918 produce greater BP reductions, with greater proportions of @entity1 achieving BP control compared with dual therapies. Further evidence also demonstrates that triple-combination therapy is efficacious for moderate to severe @entity101 , with substantial additional BP reduction over dual regimens. Both RCTs and post-marketing observational studies have shown consistent and comparable efficacy in both the general population and high-risk @entity101 subgroups. Triple therapies are generally well tolerated with adverse event profiles similar to dual regimens. In addition, fixed-dose combinations used as single pill improve @entity1 adherence leading to better long-term BP control. Depending on regional circumstances, they may also be cost effective. Thus, single-pill triple combinations of different classes of drugs with complementary mechanisms of action help to treat @entity1 to goal with improved efficacy and better adherence to treatment.Journal of @entity1 @entity101 advance online publication, 23 February 2017; doi:10.1038/jhh.2017.5.

Triple-combination therapy in the treatment of XXXX : a review of the evidence.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Human'] @entity917 :: ('MESH:C081489', 'Chemical') :: ['valsartan'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive', 'Hypertension'] @entity918 :: ('MESH:D006852', 'Chemical') :: ['hydrochlorothiazide'] @entity9885 :: ('MESH:C437965', 'Chemical') :: ['olmesartan'] @entity3591 :: ('MESH:D017311', 'Chemical') :: ['amlodipine'] @entity9887 :: ('MESH:C084178', 'Chemical') :: ['telmisartan']
@entity101 :: (MESH:D006973,Disease) :: ['hypertension']
